SCHEMBL15413005

SCHEMBL15413005

COc1cc(OC)c(Cl)c(-c2nc3cnc(Nc4c(C)cccc4[N+](=O)[O-])nc3n(C)c2=O)c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 11/20 0.52
▸ FGFR4 P22455 6/20 0.47
▸ FGFR2 P21802 3/20 0.47
▸ FGFR3 P22607 3/20 0.47
▸ CYP1A2 P05177 6/20 0.45
▸ USP2 O75604 5/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ CASP7 P55210 3/20 0.45
▸ CASP1 P29466 2/20 0.45
▸ CLK4 Q9HAZ1 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ EGFR P00533 2/20 0.44
▸ RPS6KB2 Q9UBS0 1/20 0.44
▸ CSF1R P07333 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15413205 0.87 FGFR1 (0.68) FGFR1FGFR4FGFR2FGFR3EGFR
SCHEMBL15434027 0.86 FGFR1 (0.54) FGFR1FGFR4FGFR2FGFR3CYP1A2
SCHEMBL15412800 0.81 FGFR1 (0.78) FGFR1FGFR4FGFR2FGFR3CYP1A2
SCHEMBL20705982 0.81 FGFR1 (0.49) FGFR1FGFR4FGFR2FGFR3CYP1A2
SCHEMBL15412848 0.80 FGFR1 (0.65) FGFR1FGFR4FGFR2FGFR3CYP1A2
SCHEMBL23314872 0.80 FGFR1 (0.60) FGFR1FGFR4FGFR2FGFR3CYP1A2
SCHEMBL16071791 0.80 FGFR1 (0.59) FGFR1FGFR4FGFR2FGFR3EGFR
SCHEMBL15413317 0.79 FGFR4 (0.73) FGFR1FGFR4FGFR2FGFR3CYP1A2
SCHEMBL15854314 0.77 FGFR1 (0.52) FGFR1FGFR4FGFR2FGFR3CYP1A2
SCHEMBL19470190 0.77 FGFR1 (0.52) FGFR1FGFR4FGFR2FGFR3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109627239-B Inhibitors of fibroblast growth factor receptors 缆图药品公司 2021-10-12 — — CN disclosed
EP-2872491-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2021-05-05 — — EP disclosed
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-02-05 — — US disclosed
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-02-05 — — US disclosed
US-20180362613-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2018-12-20 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9126951-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2015-09-08 — — US disclosed
EP-2872491-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR Blueprint Medicines Corporation (US) 2015-05-20 — — EP disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-03-27 — — US disclosed
WO-2014011900-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-01-16 — — WO disclosed
WO-2014011900-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR4 5/4885FGFR2 2/4885
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR4 5/4885FGFR2 2/4885
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR4 5/4885FGFR2 2/4885
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR4 5/4885FGFR2 2/4885
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR4 5/4885FGFR2 2/4885
US-20180362613-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR1 1/4885FGFR4 5/4885FGFR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback